Berberine, a plant compound increasingly promoted online as a “natural Ozempic,” does not work like modern GLP-1 medications and should not be viewed as a simple substitute for them, according to a new scientific review.
Researchers from Wroclaw Medical University analyzed the current evidence on berberine’s biological effects, focusing on its role in metabolism, inflammation and gut health. Their review, published in the International Journal of Molecular Sciences, found that the supplement’s metabolic effects appear to stem largely from interactions in the intestine rather than direct hormone signaling.
That distinction matters. GLP-1 drugs such as semaglutide act on specific receptors that regulate appetite, insulin secretion and digestion. Berberine, by contrast, does not target a single metabolic pathway.
Instead, scientists say it appears to influence metabolism indirectly by shaping the gut environment.
“The best understood is the microbiotic level and its impact on the intestinal barrier and inflammatory processes,” said Anna Duda-Madej, MD, PhD, one of the study’s authors.
In other words, the compound seems to modify the conditions in which metabolism occurs rather than directly controlling metabolic processes.
This complexity also means that berberine’s effects can vary widely from person to person. Because its activity depends heavily on gut bacteria, individual differences in the microbiome may influence how the supplement works.
“Berberine does not act in a microbiological vacuum. Its effects are largely microbiota-dependent,” Duda-Madej said.
Researchers say this variability may help explain why some people report metabolic benefits while others see little change.
The review also highlights an unusual feature of berberine: very little of it actually enters the bloodstream after oral ingestion. While this low bioavailability has sometimes been viewed as a weakness, the authors argue it may actually contribute to the compound’s effects.
Because much of the compound remains in the digestive tract, it can interact extensively with intestinal microbes and be transformed into other biologically active compounds before absorption.
“Low bioavailability after oral administration means that berberine has an intense local effect in the intestine, where it is metabolized with the participation of the microbiota,” Duda-Madej said.
The researchers also caution that berberine’s reputation as a broadly beneficial metabolic supplement is not supported by current evidence.
“The term ‘universal metabolic supplement’ is completely inaccurate,” Duda-Madej said.
Beyond questions about effectiveness, the review notes that safety issues are often overlooked in online discussions of the compound.
According to information cited from the U.S. National Center for Complementary and Integrative Health, berberine can cause gastrointestinal side effects such as nausea, abdominal pain, bloating, constipation and diarrhea. It can also interact with medications by affecting enzymes involved in drug metabolism.
These interactions may influence drugs including certain diabetes medications, anticoagulants and sedatives. The compound may also pose risks during pregnancy or breastfeeding.
Because of these potential complications, the researchers emphasize that berberine should be used cautiously and ideally under medical supervision.
Overall, the review suggests that the supplement may offer insights into how gut microbes influence metabolism, but it is far from a straightforward metabolic fix.
Rather than acting like a hormone drug, berberine appears to function as a complex modulator of interactions between the gut microbiome, inflammation and metabolic processes.
Funding information was not specified in the news release.